Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Amphetamine and Desipramine

supplement:

Amphetamine

Research Papers that Mention the Interaction

It is recommended that desmethylimipramine should be used in combination with one of the analeptic drugs ( amphetamine , ephedrine, methylphenidate, pipradrol), which are the most effective medicaments at present available for attacks of irresistible sleep.
Journal of the neurological sciences  •  1966  |  View Paper
During withdrawal from DMI, amphetamine anorexia was attenuated after 2 weeks or 2 months pretreatment, but not after 1 week of treatment.
The locomotor stimulant and stereotypy inducing effects of amphetamine were slightly enhanced during withdrawal from chronic DMI.
Psychopharmacology  •  2004  |  View Paper
Acute pretreatment with DMI and iprindole enhanced amphetamine anorexia and stereotypy; at high doses only, the enhancement of anorexia disappeared during chronic treatment.
European journal of pharmacology  •  1984  |  View Paper
The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine , which prevents the neurotoxic action of DSP4.
Neuroscience Letters  •  1983  |  View Paper
PPI is also disrupted by the norepinephrine α-1 agonist, cirazoline, and the PPI-disruptive effects of the indirect dopamine agonist amphetamine are opposed by the norepinephrine reuptake inhibitor, desipramine.
Psychopharmacology  •  2006  |  View Paper
Desipramine attenuated the increase in dopamine by amphetamine while increasing the dopamine released by methamphetamine.
Neurochemical Research  •  2004  |  View Paper
Amphetamine , at intraperitoneal doses of 0.1–3.2 mg/kg, significantly depresses the stimulated motor activity caused by combined treatment with desmethylimipramine ( DMI ) plus tetrabenazine (TBZ) in mice.
Psychopharmacologia  •  2004  |  View Paper
Our data revealed that after desipramine treatment AMPH injections not only amplified striatal DA release and 2,3-DHBA formation, but also intensified the stereotyped behaviors induced by AMPH.
Life sciences  •  1997  |  View Paper
In spontaneously beating rat atria, concentration‐dependent positive chronotropic responses to MDMA and amphetamine were blocked by the neuronaluptake inhibitor desipramine (1 μm) and the β‐adrenoceptor antagonist propranolol (1 μm).
MDMA, amphetamine and desipramine each enhanced the electrical stimulation‐induced (2 Hz, 30‐s train) release of radioactivity; the enhancing effects of MDMA and amphetamine were blocked by 1 μm desipramine.
The MDMA‐ and amphetamine‐induced release of radioactivity were blocked by 1 μm desipramine.
The Journal of pharmacy and pharmacology  •  1994  |  View Paper
It is concluded that enhancement of the anorexic effect of peripherally administered amphetamine by DMI is primarily a peripheral phenomenon, with interactions within the central nervous system making a relatively minor contribution.
Pharmacology Biochemistry and Behavior  •  1985  |  View Paper
Show More